lung cancer Non small-cell lung carcinoma
Conditions
Interventions
None listed
Sponsors
Boehringer Ingelheim
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Women and men with locally advanced, metastatic or locally recurrent NSCLC with histology of adenocarcinoma - Vargatef is initiated and administered in accordance with the SPC - Available fixed and paraffin embedded (FPE) tumour tissue routinely obtained at diagnosis and/or re-biopsy before the initiation of the first line treatment (either block or slides, minimum of 10 slides and up to 20 slides if possible at 5 um thickness).
Exclusion criteria
Exclusion criteria: - Any contraindication to Vargatef or docetaxel as specified in their respective labels - Vargatef initiated from more than 7 days prior to inclusion in this NIS - Patients participating simultaneously in another NIS or a clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival (OS). OS is defined as the time from start of entering the study to time of death (irrespective of reason). | — |
Secondary
| Measure | Time frame |
|---|---|
| Time since start of first line therapy until start of Vargatef® therapy Time since start of first line therapy until start of Vargatef® therapy is divided into 2 subgroups as follows: • *Late progression group*: time from start of first line therapy until start of Vargatef® >=9 months (T>=9) • *Early progression group*: time from start of first line therapy until start of Vargatef® | — |
Countries
Netherlands
Outcome results
None listed